BRCA1 and ovarian carcinoma: Given the recent recognition that tumors with DNA double-strand break repair defects (most notably BRCA1/2 mutations) are more sensitive to PARP inhibitors [28] and the recent approval of olaparib for advanced ovarian cancer, we undertook a comprehensive analysis of the DNA double-strand break repair pathway.